

What Oncology Clinicians Want to Know: ADDRESSING CURRENT QUESTIONS AND CONTROVERSIES IN THE MANAGEMENT OF NONCOLORECTAL GI CANCERS

CME INFORMATION

TARGET AUDIENCE

This activity is intended for medical oncologists, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

OVERVIEW OF ACTIVITY

Local and systemic treatment approaches for noncolorectal (non-CRC) GI cancers are continuously evolving. Novel molecular-targeted and biologic therapies have changed best-practice care in some instances (eg, gastric cancer, hepatocellular carcinoma, GI stromal tumors), and late-stage clinical trials have demonstrated evidence of exciting results for additional novel agents that are poised for integration into existing treatment algorithms. Thus, in addition to maintaining a sound understanding of the conventional but distinct treatment algorithms applicable to each subtype of non-CRC GI cancer, practicing oncologists must now rationally integrate targeted agents into their individualized therapeutic recommendations for the safe and effective clinical management of diseases they seldom encounter.

By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, surgeons and other healthcare providers with the formulation of up-to-date clinical management strategies for various non-CRC GI cancers.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Apply the results of emerging clinical research to the best-practice management of non-CRC GI cancers.
- Use clinical and molecular biomarkers to select optimal treatment strategies for patients with locally advanced or metastatic gastric or gastroesophageal cancer.
- Communicate the benefits and risks of existing and emerging local and systemic interventions to patients with locally advanced or metastatic hepatocellular cancer.

- Assess available and emerging research information to guide treatment decision-making for patients with metastatic GI stromal tumors.
- Recall new data with investigational agents demonstrating promising activity in non-CRC GI cancers.
- Counsel patients with non-CRC GI cancers about participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOGINonCRC14/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Charles S Fuchs, MD, MPH

Director, Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Celgene Corporation, Genentech BioOncology, Lilly, Metamark Genetics Inc, Sanofi, Takeda Pharmaceuticals North America Inc; **Consulting Agreements:** ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly.

Pamela L Kunz, MD

Assistant Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford, California

Advisory Committee and Stock Ownership: Guardant Health Inc; **Contracted Research:** Advanced Accelerator Applications, Genentech BioOncology, Lexicon Pharmaceuticals Inc, Merck, Sanofi.

J Randolph Hecht, MD

Professor of Clinical Medicine
Carol and Saul Rosenzweig Chair in Cancer
Therapies Development
Director, UCLA GI Oncology Program
Santa Monica, California

No real or apparent conflicts of interest to disclose.

Johanna C Bendell, MD

Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

No real or apparent conflicts of interest to disclose.

Alan P Venook, MD

Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California

Advisory Committee: Bayer HealthCare Pharmaceuticals; **Consulting Agreements:** Bayer HealthCare Pharmaceuticals, Sanofi; **Contracted Research:** Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Lilly, Onyx Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Incyte Corporation, Lilly, Regeneron Pharmaceuticals and Sanofi.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: April 2014

Expiration date: April 2015

SELECT PUBLICATIONS

Charles S Fuchs, MD, MPH

Aznar S et al. **Rho signals to cell growth and apoptosis.** *Cancer Lett* 2001;165(1):1-10.

Birchmeier C et al. **Met, metastasis, motility and more.** *Nat Rev Mol Cell Biol* 2003;4(12):915-25.

Cook N et al. **Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.** *Proc ASCO* 2013;**Abstract 4023.**

Ford H et al. **Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.** *Gastrointestinal Cancers Symposium* 2013;**Abstract LBA4.**

Fuchs CS et al. **Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial.** *Lancet* 2014;383(9911):31-9.

Garbay C et al. **Inhibitors of Ras signal transduction as antitumor agents.** *Biochem Pharmacol* 2000;60(8):1165-9.

Jung YD et al. **Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.** *Eur J Cancer* 2002;38(8):1133-40.

Kang JH et al. **Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.** *J Clin Oncol* 2012;30(13):1513-8.

Ma PC et al. **c-Met: Structure, functions and potential for therapeutic inhibition.** *Cancer Metastasis Rev* 2003;22(4):309-25.

Ohtsu A et al. **Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study.** *J Clin Oncol* 2011;29(30):3968-76.

Oliner K et al. **Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer.** *Proc ASCO* 2012;**Abstract 4005.**

Thuss-Patience PC et al. **Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer — A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).** *Eur J Cancer* 2011;47(15):2306-14.

Pamela L Kunz, MD

Bang YJ et al. **A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.** *Gastrointestinal Cancers Symposium* 2013;**Abstract 11.**

Bang YJ et al. **Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GE junction cancer (ToGA): A Phase 3, open-label, randomised controlled trial.** *Lancet* 2010;376(9742):687-97.

Hecht JR et al. **Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC trial.** *Proc ASCO* 2013;**Abstract LBA4001.**

Hofmann M et al. **Assessment of a HER2 scoring system for gastric cancer: Results from a validation study.** *Histopathology* 2008;52(7):797-805.

Hudis CA. **Trastuzumab — Mechanism of action and use in clinical practice.** *N Engl J Med* 2007;357(1):39-51.

J Randolph Hecht, MD

Barnett CM et al. **Gastrointestinal stromal tumors: Molecular markers and genetic subtypes.** *Hematol Oncol Clin North Am* 2013;27(5):871-88.

Blanke CD et al. **Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.** *J Clin Oncol* 2008;26(4):620-5.

Demetri GD et al. **Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): An international, multicenter, randomised, placebo-controlled, phase 3 trial.** *Lancet* 2013;381(9863):295-302.

Demetri GD et al. **Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial.** *Lancet* 2006;368(9544):1329-38.

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). **Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients.** *J Clin Oncol* 2010;28(7):1247-53.

Heinrich MC et al. **Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.** *J Clin Oncol* 2008;26(33):5352-9.

Kang JH et al. **Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.** *J Clin Oncol* 2012;30(13):1513-8.

Sircar K et al. **Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors.** *Am J Surg Pathol* 1999;23(4):377-89.

Trent JC et al. **New developments in gastrointestinal stromal tumor.** *Curr Opin Oncol* 2006;18(4):386-95.

Wang L et al. **Cellular origin of gastrointestinal stromal tumors: A study of 27 cases.** *Arch Pathol Lab Med* 2000;124(10):1471-5.

Johanna C Bendell, MD

Conroy T et al. **FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.** *N Engl J Med* 2011;364(19):1817-25.

Hoff D et al. **Randomized phase III study of weekly *nab*-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).** *Proc ASCO* 2012;**Abstract LBA148.**

Alan P Venook, MD

Lencioni R et al. **GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): Second interim analysis.** *Int J Clin Pract* 2013;[Epub ahead of print].

Lucey MR et al. **Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.** *Liver Transpl Surg* 1997;3(6):628-37.

Pugh RN et al. **Transection of the oesophagus for bleeding oesophageal varices.** *Br J Surg* 1973;60(8):646-9.

Venook AP et al. **First interim results of the global investigation of therapeutic decisions in hepatocellular carcinoma (HCC) and of its treatment with sorafenib (GIDEON) study: Use of sorafenib (Sor) by oncologists and nononcologists in the management of HCC.** *Proc ASCO* 2011;**Abstract 157.**